Packing healthy mitochondria into red blood cells: a new approach to Parkinson's disease
Parkinson's disease starts in the power plants of your cells. Scientists have now found a way to deliver healthy versions of those power plants directly to diseased brain cells, wrapped in a surprising vehicle: red blood cells.
Mitochondria are the structures that keep your cells supplied with energy. In Parkinson's disease, they become damaged or dysfunctional, triggering the death of the dopamine-producing brain cells that keep you moving smoothly. That loss of cells and energy is what drives the disease's hallmark symptoms: tremors, stiffness, and difficulty with movement. Until now, treatments have focused on compensating for the shortage of dopamine rather than repairing the mitochondria themselves.
The researchers chose red blood cells as their delivery vehicle, which sounds odd at first glance: red blood cells contain no mitochondria of their own. But that is precisely what makes them so useful. They are biologically neutral, the immune system does not flag them as a threat, and they can be repurposed as empty shells. The scientists stripped the cell membranes from red blood cells and used them to enclose functional mitochondria, then injected these capsules into disease models.
Results across multiple models
The approach was tested in several Parkinson's disease models, including both cell culture systems and animal models. In every case, improvements were observed: the mitochondria reached the diseased cells, were taken up, and measurably restored energy metabolism. In the animal models, that translated into better motor function, with the movement problems characteristic of Parkinson's disease showing clear reduction.
Mitochondrial dysfunction does not only play a role in Parkinson's disease; it is implicated in a range of other neurodegenerative conditions and in aging more broadly. A reliable method for delivering healthy mitochondria to specific cells could therefore have a wide range of applications.
From mouse to human: a long road ahead
The method does have a fundamental problem that still needs to be solved: how do you ensure that the packaged mitochondria end up in the brain rather than somewhere else in the body? The blood-brain barrier, a tightly regulated boundary between the bloodstream and brain tissue, is notoriously difficult for large molecules and structures to cross. The researchers describe their delivery method as promising, but whether it can effectively reach the human brain remains an open question.
On top of that, the study was carried out in mouse models of Parkinson's disease, which only partially replicate the human condition. Parkinson's in people is a complex, slowly progressing disease with considerable variation from one patient to the next. Whether mitochondrial damage in humans is also reversible when healthy mitochondria are supplied is something nobody yet knows.